Posted in | News | Nanomaterials | Nanobusiness

FibeRio Technology Announce Capital Raising Led by SABIC and Aster Capital

FibeRio, the developer and manufacturer of ground breaking Forcespinning® nanofiber production systems, today announced it has completed a $13M capital raise led by two global strategic investors – SABIC Ventures B.V., Saudi Basic Industries Corporation’s corporate venture capital arm, and Aster Capital Partners, sponsored by Solvay, Schneider Electric, Alstom and the European investment fund. The funding will be used to accelerate the company’s commercial growth, introduce larger scale production systems to the market and execute on a growing pipeline of orders and global opportunities with industry leading customers.

“The support of two of the leading, knowledgeable strategic investors in this space, SABIC and Aster Capital, is a strong validation of the uniqueness of our Forcespinning technology and will help the company accelerate our growth, open new markets and enable new applications for all of our customers” commented Ellery Buchanan, CEO of FibeRio. “This collaboration will greatly accelerate our vision of the Forcespinning process becoming the world’s leading, cost effective process to produce nanofibers at scale never before achieved.”

Forcespinning is a disruptive, platform technology which enables leading manufacturers to produce nanofibers on a truly commercial scale in a cost effective way using a wide range of polymers and an environmentally sensitive process.  Forcespinning is the only fine fiber production system capable of both melt and solution spinning from lab scale to full industrial scale production.  Unlike electrospinning, Forcespinning does not require materials to contain certain dielectric properties for processing which limits the materials that can be produced into fiber.  Nanofiber applications are used in a variety of markets including filtration, nonwovens, battery separators, textiles, biomedical and conductive applications.

Hans Kolnaar of SABIC Ventures commented “FibeRio’s unique processing technology not only increases our market reach, but offers SABIC an opportunity to move further down the value chain with innovative fibers for our customers.”

“We view the cost effective production of nanofibers at scale as a key technological focus for the nonwovens marketplace for a wide variety of applications in the filtration, energy, medical, hygiene and textiles markets. Thanks to our sponsor, Solvay, we were able to validate that FibeRio has a unique breakthrough technology to accelerate nanofiber growth for all levels of production. We are excited to partner with a company that will be driving the deployment of nanofibers for the foreseeable future” commented Pascal Siegwart and Todd Dauphinais, partners at Aster Capital in a joint statement.

The combined breadth of resins represented by SABIC and Aster cover everything from commodity polymers such as polypropylene and nylon to high performance materials including fluoropolymers, polysulfones, polyethylene imines, and liquid crystal polymers among others. A number of these materials have never been made into nanofibers before and can offer materials performance advantages to FibeRio Forcespinning equipment customers. FibeRio, SABIC and Solvay will all benefit through the integration of a wide range of resins with Forcespinning technology.

FibeRio’s existing shareholders also participated in this financing round, including the University of Texas System - UT Horizon Fund, the University of Texas - Pan American, the State of Texas, Silverton Partners and Cottonwood Technology Fund I. As part of this financing, James Wilson, of SABIC’s Innovative Plastics Strategic Business Unit, and Todd Dauphinais of Aster Capital will join the FibeRio board of directors

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.